Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Experimental Pharmacology and Drug Discovery

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1616144

Neurotherapeutics across Blood-Brain Barrier: Screening of BBB Permeable and CNS Active Molecules for Neurodegenerative Disease

Provisionally accepted
Mohan  Kumar DMohan Kumar DPriti  TalwarPriti Talwar*
  • School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India

The final, formatted version of the article will be published soon.

Neurotherapeutics that are effective in the central nervous system (CNS) of the brain require an accurate estimation of their uptake across the blood-brain barrier (BBB). BBB is a highly selective membrane between the bloodstream and the nervous system, that restricts and regulates the entry of small molecules. Drugs that influence the CNS, must permeate the BBB prior to reach their target site. Therefore, the prediction of BBB permeability with CNS activity is a fundamental aim and significant research objective in neuropharmacology. Here, we utilized insilico approaches and available machine learning models ranging from physicochemical properties to structureactivity relationships, in a CNS drug discovery pipeline to identify BBB permeable molecules.These models pertain to pharmacophore-based virtual screening, BBB permeability and CNS activity prediction, medicinal chemistry, ADME, Toxicity profiling, drug-likeness, side effect resources, and bioactivity studies. A total of 2127 active small molecules were screened initially based on the structure similarity of five FDA-approved drugs of particular interest for neurodegenerative diseases. Based on the BBB model, it was classified into 582 BBB permeable and 1545 BBB non-permeable molecules. Most of the BBB-permeable molecules were reported to have direct CNS activity due to their high brain-to-blood ratio. Finally, 112 active CNS molecules were prioritized based on the following studies, such as pharmacokinetics, toxicophores, and drug-likeness. Additionally, neuroactivity towards the CNS of small molecules was predicted to be a nootropic, neurotrophic factor enhancer, and neuroinflammatory modulator. Thus, by ensuring their impact on BBB integrity and neuroprotective properties of small molecules, they can be transformed into food supplements and nutraceuticals in the future that could provide valuable insight into neurotherapeutics, as promising therapeutic interventions for neurodegenerative diseases.

Keywords: neurotherapeutics, BBB permeable, CNS active, small molecules, Drug Discovery, pharmacokinetics, Neurotrophic factor

Received: 24 Apr 2025; Accepted: 19 Aug 2025.

Copyright: © 2025 D and Talwar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Priti Talwar, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, 632014, Tamil Nadu, India

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.